MediumEndocrinologyType 2 diabetes with cardiovascular diseaseau-amcau-racp
A 63-year-old man with type 2 diabetes, eGFR 58 mL/min/1.73 m² and a prior myocardial infarction is on metformin and maximally tolerated ACE inhibitor and beta blocker. His HbA1c is 56 mmol/mol. Which additional glucose-lowering agent would provide the greatest cardiovascular and renal benefit according to current Australian recommendations?